Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: 0565 • ACR Convergence 2021
Increased Risk for Inflammatory Arthritis in Veterans with Depression or Anxiety
Brian Breviu¹, Shaobo Pei¹, Matthew Kirkpatrick², Bingjian Feng¹ and Jessica Walsh³, ¹Salt Lake City Veteran Affairs and University of Utah Medical Centers, Salt Lake City, UT, ²University of Utah, Salt Lake City, UT, ³Salt Lake City Veteran Affairs Medical Center (VAMC)/University of Utah Hospital, Salt Lake City, UT
Background/Purpose: Depression and anxiety are common in patients with inflammatory arthritis (IA), and have been reported as risk factors for various inflammatory diseases. The study…
Abstract Number: 0907 • ACR Convergence 2021
Radiographic Sacroiliitis Progression up to Six Years of Follow-Up in Patients with Non-Radiographic Axial Apondyloarthritis
Stan Kieskamp¹, Rick Wilbrink², Freke Wink³, Reinhard Bos⁴, Hendrika Bootsma¹, Suzanne Arends¹ and Anneke Spoorenberg¹, ¹University Medical Center Groningen, Groningen, Netherlands, ²University of Groningen, Leeuwarden, Netherlands, ³Medical Center Leeuwarden, Leeuwarden, Netherlands, ⁴Department of Rheumatology, Medical Centre Leeuwarden, Leeuwarden, Netherlands
Background/Purpose: In two years, approximately 10% of patients with non-radiographic axial spondyloarthritis (nr-axSpA) progresses to ankylosing spondylitis (AS). There are no data available of more…
Abstract Number: 0938 • ACR Convergence 2021
Comparative Effectiveness and Treatment Survival of Different TNF Inhibitors for Axial Spondyloarthritis in Real-World Clinical Practice
Javier Marrugo¹, Maude Bonin¹, Gilles Boire¹, Louis Bessette² and Ariel Masetto¹, ¹Universite de Sherbrooke, Sherbrooke, QC, Canada, ²Centre de l'Ostoporose et de Rhumatologie de Qubec, Québec City, QC, Canada
Background/Purpose: Tumor necrosis factor (TNF) inhibitors are the mainstay treatment for NSAID refractory axial spondyloarthritis (axSpA). However, few data exist on their use during routine…
Abstract Number: 1788 • ACR Convergence 2021
Improving Care and Capacity Through Capturing and Recording Patient Reported Outcomes with Digital Solutions in Spondyloarthritis
Antoni Chan¹, Kathryn Rigler¹ and Liz van Rossen², ¹Royal Berkshire NHS Foundation Trust, Reading, United Kingdom, ²East Kent NHS Foundation Trust, Kent, United Kingdom
Background/Purpose: Patient-reported outcomes (PROs) have always been at the forefront for the assessment of spondyloarthritis (SpA) which includes axial Spa (axSpA) and psoriatic arthritis (PsA).…
Abstract Number: 0048 • ACR Convergence 2021
A Novel Technology to Study the Role of Intestinal Biology in Spondyloarthritis Pathogenesis: Human Colonic Organoids and Epithelial Monolayers
Manuel Rodriguez¹, Alec Furst¹, James T. Rosenbaum² and Tejpal Gill¹, ¹Oregon Health & Science University, Portland, OR, ²Departments of Ophthalmology, Medicine, and Cell Biology, Oregon Health & Sciences University and Chair Emeritus, Legacy Devers Eye Institute, Portland, OR
Background/Purpose: Ankylosing spondylitis (AS) is a complex genetic disease with strong association to the human leukocyte antigen (HLA)-B27. Several observations including frequent, occult histologic evidence…
Abstract Number: 0363 • ACR Convergence 2021
Disease Course and Disease Burden in Patients with Axial Spondyloarthritis: Results from 5-year Multicountry Prospective Observational Study
Denis Poddubnyy¹, Joachim Sieper², Servet Akar³, Santiago Muñoz-Fernández⁴, Hildrun Haibel², Fabiana Ganz⁵ and Robert Inman⁶, ¹Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany, ²Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ³Izmir Katip Celebi University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Izmir, Turkey, ⁴Servicio de Reumatología, Hospital Universitario Infanta Sofía, Madrid, Spain, ⁵Abbvie Inc., North Chicago, IL, ⁶University Health Network, Toronto, ON, Canada
Background/Purpose: Patients (pts) with axial SpA (axSpA) can be classified into radiographic axSpA (r-axSpA) and non-radiographic axSpA (nr-axSpA) based on the presence or absence of…
Abstract Number: 0569 • ACR Convergence 2021
All-Cause and Cause-Specific Mortality in Spondyloarthritis: A Systematic Review and Meta-Analysis
Haseeb Chaudhary¹, Nidrit Bohra², Khezar Syed², Anthony Donato², M.Hassan Murad³ and Paras Karmacharya⁴, ¹Tower Health System, Reading, PA, ²Reading Hospital, Tower Health System, Reading, PA, ³Mayo Clinic, Rochester, MN, ⁴Division of Rheumatology, Mayo Clinic, Rochester, MN Division of Rheumatology, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Spondyloarthritides (SpA) represent a group of chronic inflammatory diseases associated with a higher risk of cardio-metabolic comorbidities compared to the general population. It is…
Abstract Number: 0908 • ACR Convergence 2021
Evaluation of the Nonsteroidal Anti-Inflammatory Drug-Sparing Effect of Secukinumab in Patients with Ankylosing Spondylitis: Multicenter, Randomised, Double-blind, Phase IV Study
Uta Kiltz¹, Xenofon Baraliakos¹, Jan Brandt-Jrgens², Ulf Wagner³, Sebastian Lieb⁴, Christian Sieder⁵, Christian Mann⁵ and Jürgen Braun¹, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ²Rheumatologische Schwerpunktpraxis, Berlin, Germany, ³Universitätsklinikum Leipzig, Leipzig, Germany, ⁴Novartis Pharma GmbH, Immunology, Hepatology and Dermatology, Nürnberg, Germany, ⁵Novartis Pharma GmbH, Nürnberg, Germany
Background/Purpose: Nonsteroidal anti-inflammatory drugs (NSAIDs) are used to treat inflammatory back pain in patients (pts) with ankylosing spondylitis (AS). However, an increased risk of side…
Abstract Number: 0947 • ACR Convergence 2021
Cytokine Competent Gut-joint Migratory T Cells Contribute to Inflammation in the Joint
Adam Lefferts¹, David Claypool¹, Eric Norman¹, Uma Kantheti¹ and Kristine Kuhn², ¹University of Colorado, Anschutz Medical Campus, Aurora, CO, ²University of Colorado Anschutz Medical Campus, Aurora, CO
Background/Purpose: Although studies have identified the presence of gut-associated cells in the enthesis of joints affected by spondyloarthritis, a direct link through cellular transit between…
Abstract Number: 1802 • ACR Convergence 2021
Comparison of Axial and Peripheral Manifestations in Patients with Psoriatic Arthritis and Ankylosing Spondylitis in Upadacitinib Clinical Trials
Xenofon Baraliakos¹, Atul Deodhar², Roberto Ranza³, Simona Rednic⁴, Francesco Ciccia⁵, Fabiana Ganz⁶, Tianming Gao⁶, Apinya Lertratanakul⁶, In-Ho Song⁶, Andrew Ostor⁷ and Laura Coates⁸, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ²Oregon Health & Science University, Portland, OR, ³Hospital de Clinicas, Universidade Federal de Uberlândia, Uberlandia, MG, Brazil, ⁴Emergency Clinical County Hospital, Rheumatology and Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania, ⁵University of Campania “Luigi Vanvitelli", Naples, Italy, ⁶Abbvie Inc., North Chicago, IL, ⁷Monash University, Cabrini Hospital, and Emertius Research, Malvern, Australia, ⁸Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom
Background/Purpose: Axial, peripheral, and other disease manifestations often overlap between psoriatic arthritis (PsA) and ankylosing spondylitis (AS). Upadacitinib (UPA) is an oral Janus kinase inhibitor…
Abstract Number: 0050 • ACR Convergence 2021
Integrative Analysis of mRNAs to Identify Sex Differences in Th-17 Mediated Inflammation in Ankylosing Spondylitis
Maricela Haghiac¹, Maya Breitman², Ricky Chan³, Ahmad Khalil³ and Marina Magrey⁴, ¹Metrohealth Medical center, Cleveland, OH, ²MetroHealth Medical Center,Case Western Reserve University School of Medicine, Cleveland, OH, ³Case Western Reserve University, Cleveland, OH, ⁴Case Western Reserve University, MetroHealth Medical Center, Cleveland, OH, USA, Richfield, OH
Background/Purpose: Gender has been shown to impact disease expression in ankylosing spondylitis. Men with AS are more likely to develop radiographic joint damage, while women…
Abstract Number: 0366 • ACR Convergence 2021
Why Is It so Difficult for AxSpA Patients to Find a Job? Results from the European Map of Axial Spondyloarthritis (EMAS)
Marco Garrido-Cumbrera¹, Victoria Navarro-Compán², Christine Bundy³, Souzi Makri⁴, Laura Christen⁵, José Correa-Fernández⁶, Sergio Sanz-Gomez⁶, Raj Mahapatra⁷, Carlos Jesús Delgado-Domínguez⁶ and Denis Poddubnyy⁸, ¹Health & Territory Research (HTR), University of Seville, Sevilla, Spain, ²Rheumatology service, Hospital Universitario La Paz-IdiPaz, Madrid, Spain, ³Cardiff University, Cardiff, Wales, United Kingdom, ⁴Cyprus League Against Rheumatism (CYPLAR), Limassol, Cyprus, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶Health & Territory Research (HTR), Universidad de Sevilla, Seville, Spain, ⁷Axial Spondyloarthritis International Federation (ASIF), London, United Kingdom, ⁸Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany
Background/Purpose: AxSpA is associated with substantial negative consequences regarding work status and career prospects. The aim is to identify factors associated with barriers to job…
Abstract Number: 0573 • ACR Convergence 2021
Biosimilar to Biosimilar Infliximab Switching in Real-world Patients with Inflammatory Arthritis Followed in the Danish DANBIO Registry: Switch from Originator Infliximab to CT-P13 and Then to GP1111
Hafsah Nabi¹, Bente Glintborg², Anne Gitte Loft³, Oliver Hendricks⁴, Jens Kristian Pedersen⁵, Søren Andreas Just⁶, Rabiah Ahmed⁷, Kamilla Danebod⁷, Heidi Munk⁸, Ada Colic⁹, Asta Linauskas¹⁰, Dorte Vendelbo Jensen¹¹, Johnny Raun¹², Jolanta Grydehøj¹³, Louise Brot Christensen¹⁴, Natalia Manilo¹⁵, Niels Lomborg¹⁶, Salome Kristensen¹⁷, Frank Mehnert¹⁸, Niels Steen Krogh¹⁹ and Merete Hetland²⁰, ¹DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Rigshospitalet, Copenhagen, Denmark, ²COPECARE, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, Glostrup, Denmark, ³Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ⁴Danish Hospital for Rheumatic Diseases, University Hospital of Southern Denmark, Snderborg, Denmark, ⁵Section of Rheumatology, Department of Medicine, Svendborg Hospital – Odense University Hospital, Svendborg, Denmark, ⁶Section of Rheumatology, Dept. of Medicine, Svendborg Hospital, Svendborg, Denmark, ⁷Department of Rheumatology, Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Rigshospitalet, Copenhagen University Hospital, Glostrup, Copenhagen, Denmark, ⁸Department of Rheumatology, Odense University Hospital, Odense, Denmark, ⁹Department of Rheumatology, Zealand University Hospital, Køge, Denmark, ¹⁰Department of Rheumatology, North Denmark Regional Hospital, Hjoerring, Denmark, ¹¹Department of Internal Medicine, Rønne Hospital, Rønne, Denmark, ¹²Department of Rheumatology, Sygehus Lillebælt, Fredericia, Denmark, ¹³Department of Rheumatology, Holstebro Hospital, Holstebro, Denmark, ¹⁴Department of Rheumatology, Gentofte and Herlev Hospital, Copenhagen University Hospital, Gentofte, Denmark, ¹⁵Department of Rheumatology, Frederiksberg Hospital, Frederiksberg, Denmark, ¹⁶Department of Rheumatology, Vejle Hospital Lillebælt, Vejle, Odense C, Denmark, ¹⁷Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, ¹⁸Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark, ¹⁹ZiteLab ApS, Copenhagen, Denmark, Frederiksberg, Denmark, ²⁰DANBIO and COPECARE, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark
Background/Purpose: In routine care, biosimilar to biosimilar infliximab switching may occur to save costs (=non-medical switching). Previous studies have investigated the efficacy and safety of…
Abstract Number: 0909 • ACR Convergence 2021
How Does Gender Affect Secukinumab Treatment Outcomes and Retention Rates in Patients with Ankylosing Spondylitis? – Real World Data from a German Observational Study
Uta Kiltz¹, Jan Brandt-Jrgens², Peter Kästner³, Elke Riechers⁴, Daniel Peterlik⁵ and Hans-Peter Tony⁶, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ²Rheumatologische Schwerpunktpraxis, Berlin, Germany, ³Ambulantes Rheumazentrum Erfurt, Erfurt, Germany, ⁴Department for Rheumatology and Immunology, Hannover Medical University, Hannover, ⁵Novartis Pharma GmbH, Nürnberg, Germany, ⁶Universitätsklinikum Würzburg, Wuerzburg, Germany
Background/Purpose: Current studies suggest that the phenotype of spondyloarthritis differs between genders and that this may influence the subsequent diagnostic approach and therapeutic decisions1. The…
Abstract Number: 0990 • ACR Convergence 2021
Lower Incidence of COVID-19 but Higher Mortality in Patients with Inflammatory Arthritis Compared to Controls in Wales, United Kingdom: A Population Epidemiological Study
Roxanne Cooksey¹, Mark Atkinson² and Ernest Choy³, ¹Cardiff University, Cardiff, Wales, United Kingdom, ²Swansea University, Swansea, Wales, United Kingdom, ³CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom
Background/Purpose: The COVID-19 pandemic has caused over 3 million deaths. Having inflammatory arthritis (IA) and anti-rheumatic medications increase the risk of infections. Comorbidities, common in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].